Browse > Article
http://dx.doi.org/10.4070/kcj.2014.44.1.42

Myocardial Infarction Type 4b in Human Immunodeficiency Virus-Infected Patient  

Cybula-Walczak, Aneta (Department of Hepatology and Acquired Immunodeficiencies, Medical University of Warsaw)
Szymanski, Filip M. (Department of Cardiology, Medical University of Warsaw)
Platek, Anna E. (Department of Cardiology, Medical University of Warsaw)
Karpinski, Grzegorz (Department of Cardiology, Medical University of Warsaw)
Publication Information
Korean Circulation Journal / v.44, no.1, 2014 , pp. 42-44 More about this Journal
Abstract
We report a case of a 52-year-old human immunodeficiency virus (HIV)-infected male patient receiving combined antiretroviral therapy (cART), who presented with acute ST-elevation myocardial infarction (STEMI). He was properly treated (e.g., prescribed anti-coagulation drugs: aspirin, clopidogrel, enoxaparin) and discharged. After 1.5 months, another STEMI related with in-stent thrombosis took place. The cART scheme was altered, resulting in no further cardiac events in the follow-up period, with undetectable levels of HIV ribonucleic acid. This case highlights the association between HIV infection and the specific drugs of cART, and the risk of cardiovascular disease development.
Keywords
Human immunodeficiency virus; Myocardial infarction; Antiretroviral therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.   DOI
2 Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double- blind, randomised controlled trial. Lancet 2009;373:723-31.   DOI   ScienceOn
3 Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and metaanalysis. HIV Med 2012;13:453-68.
4 DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356: 1723-35.   DOI   ScienceOn
5 Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228-38.   DOI   ScienceOn
6 Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV- 1-infected patients at week 48. AIDS 2008;22:1389-97.   DOI   ScienceOn
7 Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011;32:945-51.   DOI
8 Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013;61:511-23.   DOI
9 Hrynkiewicz-Szymanska A, Szymanski FM, Filipiak KJ, et al. Can obstructive sleep apnea be a cause of in-stent thrombosis? Sleep Breath 2011;15:607-9.   DOI
10 Deeks SG, Gandhi RT, Chae CU, Lewandrowski KB. Case records of the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain. N Engl J Med 2012;367: 1246-54.   DOI